These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38884158)

  • 1. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
    Chee L; Lee N; Grigg A; Chen M; Schwarer A; Szer J; Ratnasingam S; Raj S; Lukito P; Yeung D; Hughes T; Shanmuganathan N
    Intern Med J; 2024 Jul; 54(7):1214-1218. PubMed ID: 38884158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
    N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
    Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
    Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
    Eide CA; Brewer D; Xie T; Schultz AR; Savage SL; Muratcioglu S; Merz N; Press RD; O'Hare T; Jacob T; Vu TQ; Tognon CE; Macey TA; Kuriyan J; Kalodimos CG; Druker BJ
    Cancer Cell; 2024 Sep; 42(9):1486-1488. PubMed ID: 39214096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
    García-Gutiérrez V; Hernandez-Boluda JC
    Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
    Minami Y; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Dawson MK; Matsumura I
    Int J Hematol; 2024 Sep; 120(3):305-313. PubMed ID: 38888812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.
    Yoshida C; Takaku T
    Med; 2024 Aug; 5(8):856-858. PubMed ID: 39127034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP;
    N Engl J Med; 2024 Sep; 391(10):885-898. PubMed ID: 38820078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
    Okabe S; Moriyama M; Gotoh A
    Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
    Cortes JE; Sasaki K; Kim DW; Hughes TP; Etienne G; Mauro MJ; Hochhaus A; Lang F; Heinrich MC; Breccia M; Deininger M; Goh YT; Janssen JJWM; Talpaz M; de Soria VGG; le Coutre P; DeAngelo DJ; Damon A; Cacciatore S; Polydoros F; Agrawal N; Rea D
    Leukemia; 2024 Jul; 38(7):1522-1533. PubMed ID: 38755421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
    Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
    Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
    Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
    Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asciminib for chronic myeloid leukaemia: Next questions.
    Shanmuganathan N; Hughes TP
    Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
    Leyte-Vidal A; Garrido Ruiz D; DeFilippis R; Leske IB; Rea D; Phan S; Miller KB; Hu F; Mase A; Shan Y; Hantschel O; Jacobson MP; Shah NP
    Blood; 2024 Aug; 144(6):639-645. PubMed ID: 38643492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Luna A; Pérez-Lamas L; Boque C; Giraldo P; Xicoy B; Ruiz Nuño C; Vega MM; Alvarez-Larrán A; Salamanca A; García-Noblejas A; Vall-Llovera F; Villalon L; De Las Heras N; Ramila E; Pérez-Encinas M; Cuevas B; Perez-Lopez R; Sanchez-Guijo F; Jiménez-Velasco A; Lakhwani S; Casado LF; Rosell A; Escola A; Fernández MJ; Garcia-Hernandez C; Cervero C; Mora E; Sagüés M; Suarez-Varela S; Vélez P; Carrascosa Mastell P; Bitaube RF; Serrano L; Cortes M; Vera Goñi JA; Steegmann JL; de Soria VGG; Alonso-Dominguez JM; Araujo MC; Coll AP; Hernandez-Boluda JC; García-Gutiérrez V
    Ann Hematol; 2022 Oct; 101(10):2263-2270. PubMed ID: 35997804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
    Réa D; Hughes TP
    Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
    Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
    Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
    Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.